{
  "title": "Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final resultsCirculating tumor DNA as a clinical test in resected pancreatic cancerAssociation of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinomaPancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985\u20131995, using the National Cancer DatabaseOptimized anchor-modified peptides targeting mutated RAS are promising candidates for immunotherapyHigh-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12DGeneration of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discoveryFrom sewer to saviour\u2014targeting the lymphatic system to promote drug exposure and activityStructure-based programming of lymph-node targeting in molecular vaccinesLymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trialMeasuring diagnostic and predictive accuracy in disease management: an introduction to receiver operating characteristic (ROC) analysisPersonalized RNA neoantigen vaccines stimulate T cells in pancreatic cancerRNA neoantigen vaccines prime long-lived CD8 T cells in pancreatic cancerT-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 studyPersonalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trialA neoantigen vaccine generates antitumour immunity in renal cell carcinomaCirculating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancerDistinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancerDistinct molecular and clinical features of specific variants of KRAS codon 12 in pancreatic adenocarcinomaEradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responsesLymph node\u2013targeted vaccine boosting of TCR T-cell therapy enhances antitumor function and eradicates solid tumorsVaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneityJoint confidence region estimation for area under ROC curve and Youden index",
  "pmcid": "12618236",
  "features": {
    "sample_size": {
      "present": true,
      "count": 5,
      "unique_matches": [
        "n\u2009=\u20096",
        "n\u2009=\u20098",
        "n\u2009=\u200917",
        "n\u2009=\u200921",
        "n\u2009=\u200919"
      ],
      "examples": [
        {
          "match": "n\u2009=\u200921",
          "context": "a from all T cell responders (n\u2009=\u200921/25). Figure 2b contains data"
        },
        {
          "match": "n\u2009=\u200919",
          "context": "ponders with FluoroSpot data (n\u2009=\u200919/25) while Fig. 2c contains da"
        },
        {
          "match": "n\u2009=\u200917",
          "context": "all responders with ICS data (n\u2009=\u200917/25). Figure 2g contains data"
        }
      ]
    },
    "randomization": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "blinding": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "allocation_concealment": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "interaction_subgroup": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "heterogeneity"
      ],
      "examples": [
        {
          "match": "heterogeneity",
          "context": "to reject tumors with antigen heterogeneityJoint confidence region estima"
        }
      ]
    },
    "variable_definitions": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "primary endpoint"
      ],
      "examples": [
        {
          "match": "Primary endpoint",
          "context": "ollect additional RFS and OS. Primary endpoints of the study were safety (ad"
        }
      ]
    },
    "analysis_principles": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "itt_details": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "software": {
      "present": true,
      "count": 4,
      "unique_matches": [
        "flowjo",
        "sas",
        "r, 0.7",
        "graphpad prism"
      ],
      "examples": [
        {
          "match": "SAS",
          "context": "a logistic regression model. SAS v9.4 and R v4.4.3 were used t"
        },
        {
          "match": "R, 0.7",
          "context": "Amph-Peptides 2P (G12D and G12R, 0.7\u2009mg each) was administered wit"
        },
        {
          "match": "GraphPad Prism",
          "context": "perform statistical analysis. GraphPad Prism v9.4 was used to create Figs."
        }
      ]
    },
    "error_measures": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "multiplicity_correction": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "normality_checks": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "p_values": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "confidence_intervals": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "comparative_stats": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "non_parametric": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "advanced_modeling": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "assumption_checks": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "survival_analysis": {
      "present": true,
      "count": 6,
      "unique_matches": [
        "log-rank",
        "rfs",
        "os"
      ],
      "examples": [
        {
          "match": "log-rank",
          "context": "e survival distributions. The log-rank test was used to compare the"
        },
        {
          "match": "RFS",
          "context": "llow-up to collect additional RFS and OS. Primary endpoints of"
        },
        {
          "match": "RFS",
          "context": "test was used to compare the RFS between the high and low T ce"
        }
      ]
    },
    "regression_and_models": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "logistic regression"
      ],
      "examples": [
        {
          "match": "logistic regression",
          "context": "nalysis was performed using a logistic regression model. SAS v9.4 and R v4.4.3"
        }
      ]
    },
    "reporting_guidelines": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "data_types": {
      "present": true,
      "count": 3,
      "unique_matches": [
        "categorical",
        "continuous"
      ],
      "examples": [
        {
          "match": "Categorical",
          "context": "imum value and maximum value. Categorical variables were summarized usi"
        },
        {
          "match": "categorical",
          "context": "examined for association with categorical variables, including high ver"
        },
        {
          "match": "Continuous",
          "context": "ical history and safety data. Continuous variables were summarized usi"
        }
      ]
    },
    "dependency": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "clustering": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "missing_data": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "effect_size": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "post_hoc": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "baseline_reporting": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "table 1"
      ],
      "examples": [
        {
          "match": "Table 1",
          "context": "\u22121 per peptide (Supplementary Table 1). GolgiStop and GolgiPlug (BD"
        },
        {
          "match": "Table 1",
          "context": "uences found in Supplementary Table 1). Descriptive statistics were"
        }
      ]
    },
    "advanced_modeling_extra": {
      "present": true,
      "count": 5,
      "unique_matches": [
        "excluded"
      ],
      "examples": [
        {
          "match": "excluded",
          "context": "electroporation permitted. We excluded patients who received antitum"
        },
        {
          "match": "excluded",
          "context": "eks of SARS-CoV-2. Women were excluded if pregnant or lactating. PDA"
        },
        {
          "match": "excluded",
          "context": "lactating. PDAC patients were excluded when tumors were of neuroendo"
        }
      ]
    },
    "systematic_review_metrics": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "diagnostic_metrics": {
      "present": true,
      "count": 3,
      "unique_matches": [
        "roc"
      ],
      "examples": [
        {
          "match": "ROC",
          "context": "ver operating characteristic (ROC) analysisPersonalized RNA neo"
        },
        {
          "match": "ROC",
          "context": "ion estimation for area under ROC curve and Youden index  A pha"
        },
        {
          "match": "ROC",
          "context": "low T cell responders and the ROC analysis was performed using"
        }
      ]
    },
    "model_details": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "domain_indicators": {
      "present": true,
      "count": 4,
      "unique_matches": [
        "flow cytometry",
        "staining",
        "mice"
      ],
      "examples": [
        {
          "match": "mice",
          "context": "f large established tumors in mice by combination immunotherapy"
        },
        {
          "match": "staining",
          "context": "in the intracellular cytokine staining (ICS) assay (n\u2009=\u20096/8). A dire"
        },
        {
          "match": "staining",
          "context": "he FoxP3/transcription factor staining buffer set (Thermo Fisher Sci"
        }
      ]
    }
  },
  "feedback": {
    "overall_score": 5.5,
    "rigor_rating": "Medium",
    "critical_gaps": [
      {
        "message": "Survival analysis used without verifying proportional hazards assumption.",
        "evidence": "...e survival distributions. The log-rank test was used to compare the..."
      },
      {
        "message": "Data exclusion criteria should be explicitly detailed.",
        "evidence": "...electroporation permitted. We excluded patients who received antitum..."
      },
      {
        "message": "Diagnostic metrics reported without Confidence Intervals.",
        "evidence": "...ver operating characteristic (ROC) analysisPersonalized RNA neo..."
      }
    ],
    "strengths": [
      {
        "message": "Analysis context identifies basic science or bioinformatics (Softened clinical trial requirements).",
        "evidence": "Detected term: 'flow cytometry'"
      },
      {
        "message": "Detailed software versions provided.",
        "evidence": "...a logistic regression model. SAS v9.4 and R v4.4.3 were used t..."
      },
      {
        "message": "Reported diagnostic metrics (AUC/ROC).",
        "evidence": "...ver operating characteristic (ROC) analysisPersonalized RNA neo..."
      }
    ],
    "actionable_recommendations": [],
    "deterministic_audit": true
  }
}